Deoxycytidylyl-3',5'-guanosine
Star0
Identification
- Generic Name
- Deoxycytidylyl-3',5'-guanosine
- DrugBank Accession Number
- DB03326
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 556.4232
Monoisotopic: 556.143125572 - Chemical Formula
- C19H25N8O10P
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism URibonuclease pancreatic Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as (3'->5')-dinucleotides. These are dinucleotides where the two bases are connected via a (3'->5')-phosphodiester linkage.
- Kingdom
- Organic compounds
- Super Class
- Nucleosides, nucleotides, and analogues
- Class
- (3'->5')-dinucleotides and analogues
- Sub Class
- (3'->5')-dinucleotides
- Direct Parent
- (3'->5')-dinucleotides
- Alternative Parents
- Purine 2'-deoxyribonucleoside monophosphates / Purines and purine derivatives / Hydroxypyrimidines / Dialkyl phosphates / N-substituted imidazoles / Hydropyrimidines / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds show 6 more
- Substituents
- (3'->5')-dinucleotide / Alcohol / Alkyl phosphate / Aromatic heteropolycyclic compound / Azacycle / Azole / Dialkyl phosphate / Heteroaromatic compound / Hydrocarbon derivative / Hydropyrimidine show 20 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 52474-59-6
- InChI Key
- OBCJQWSXSLYWHI-GVKYBDNRSA-N
- InChI
- InChI=1S/C19H25N8O10P/c20-12-1-2-26(19(31)23-12)14-4-9(10(5-28)35-14)37-38(32,33)34-6-11-8(29)3-13(36-11)27-7-22-15-16(27)24-18(21)25-17(15)30/h1-2,7-11,13-14,28-29H,3-6H2,(H,32,33)(H2,20,23,31)(H3,21,24,25,30)/t8-,9?,10?,11+,13+,14?/m0/s1
- IUPAC Name
- {[5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy}({[(2R,3S,5R)-5-(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy})phosphinic acid
- SMILES
- NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OC2CC(OC2CO)N2C=CC(N)=NC2=O)O1
References
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -2.6 Chemaxon pKa (Strongest Acidic) 1.75 Chemaxon pKa (Strongest Basic) 4.3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 14 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 258.67 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 122.8 m3·mol-1 Chemaxon Polarizability 50.01 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.8397 Blood Brain Barrier + 0.8446 Caco-2 permeable - 0.7196 P-glycoprotein substrate Substrate 0.5773 P-glycoprotein inhibitor I Non-inhibitor 0.826 P-glycoprotein inhibitor II Non-inhibitor 0.981 Renal organic cation transporter Non-inhibitor 0.894 CYP450 2C9 substrate Non-substrate 0.7892 CYP450 2D6 substrate Non-substrate 0.8267 CYP450 3A4 substrate Substrate 0.5159 CYP450 1A2 substrate Non-inhibitor 0.7954 CYP450 2C9 inhibitor Non-inhibitor 0.8492 CYP450 2D6 inhibitor Non-inhibitor 0.9093 CYP450 2C19 inhibitor Non-inhibitor 0.885 CYP450 3A4 inhibitor Non-inhibitor 0.6137 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9205 Ames test Non AMES toxic 0.6684 Carcinogenicity Non-carcinogens 0.7746 Biodegradation Not ready biodegradable 0.9911 Rat acute toxicity 2.5306 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9355 hERG inhibition (predictor II) Non-inhibitor 0.6499
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsRibonuclease pancreatic
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Ribonuclease a activity
- Specific Function
- Endonuclease that catalyzes the cleavage of RNA on the 3' side of pyrimidine nucleotides. Acts on single-stranded and double-stranded RNA.
- Gene Name
- RNASE1
- Uniprot ID
- P07998
- Uniprot Name
- Ribonuclease pancreatic
- Molecular Weight
- 17644.125 Da
References
- Listgarten JN, Maes D, Wyns L, Aguilar CF, Palmer RA: Structure of the crystalline complex of deoxycytidylyl-3',5'-guanosine (3',5'-dCpdG) cocrystallized with ribonuclease at 1.9 A resolution. Acta Crystallogr D Biol Crystallogr. 1995 Sep 1;51(Pt 5):767-71. [Article]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52